Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 1/20 | 1.00 |
| ▸ | AKR1B1 | P15121 | 12/20 | 0.73 |
| ▸ | AKR1A1 | P14550 | 10/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | HRH1 | P35367 | 1/20 | 0.59 |
| ▸ | SCN1A | P35498 | 1/20 | 0.59 |
| ▸ | SCN4A | P35499 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.59 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.59 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.59 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.59 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31195728 | 1.00 | ITGA4 (1.00) | ITGA4AKR1B1AKR1A1CYP2C9CACNA1F | |
| SCHEMBL21095655 | 0.85 | ITGA4 (0.73) | ITGA4AKR1B1AKR1A1CYP2C9CACNA1F | |
| SCHEMBL9811052 | 0.85 | ITGA4 (0.73) | ITGA4AKR1B1AKR1A1CYP2C9CACNA1F | |
| SCHEMBL9671834 | 0.85 | ITGA4 (0.73) | ITGA4AKR1B1AKR1A1CYP2C9CACNA1F | |
| SCHEMBL9811062 | 0.85 | ITGA4 (0.73) | ITGA4AKR1B1AKR1A1CYP2C9CACNA1F | |
| SCHEMBL10930167 | 0.85 | AKR1A1 (1.00) | ITGA4AKR1B1AKR1A1CYP2C9CACNA1F | |
| SCHEMBL9810979 | 0.85 | AKR1B1 (0.83) | ITGA4AKR1B1AKR1A1CYP2C9CACNA1F | |
| SCHEMBL21095641 | 0.85 | ITGA4 (0.73) | ITGA4AKR1B1AKR1A1CYP2C9CACNA1F | |
| SCHEMBL21095561 | 0.85 | ITGA4 (0.73) | ITGA4AKR1B1AKR1A1CYP2C9CACNA1F | |
| SCHEMBL9810970 | 0.85 | ITGA4 (0.73) | ITGA4AKR1B1AKR1A1CYP2C9CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0092385-B1 | HYDANTOIN DERIVATIVES FOR USE IN INHIBITING ALDOSE REDUCTASE ACTIVITY, COMPOSITIONS THEREFOR AND PROCESS FOR PREPARING SPIRO-FLUOREN COMPOUNDS | ALCON LABORATORIES, INC. (US) | 1991-06-12 | — | — | EP | claimed |
| US-4540700-A | Treatment of diabetic complications with certain spiro-imidazolidine-diones | ALCON LABORATORIES, INC. (US) | 1985-09-10 | — | — | US | claimed |
| US-4438272-A | COMPLICATIONS OF DIABETES | ALCON LABORATORIES, INC. (US) | 1984-03-20 | — | — | US | claimed |
| US-4436745-A | TETRACYCLIC SPIROHYDANTOINS | ALCON LABORATORIES, INC. (US) | 1984-03-13 | — | — | US | claimed |
| WO-1983003543-A1 | METHOD OF INHIBITING ALDOSE REDUCTASE ACTIVITY, COMPOSITIONS THEREFOR AND PROCESS FOR PREPARING SPIRO-FLUOROFLUOREN AND SPIRO-DIFLUOROFLUOREN COMPOUNDS | ALCON LAB INC (US) | 1983-10-27 | — | — | WO | claimed |
| EP-0092385-A2 | Hydantoin derivatives for use in inhibiting aldose reductase activity, compositions therefor and process for preparing spiro-fluoren compounds | ALCON LABORATORIES, INC. (US) | 1983-10-26 | — | — | EP | claimed |
| US-12091554-B2 | Substituted polyfluorene compounds | BioLegend, Inc. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20230190710-A1 | COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 | UNIV CASE WESTERN RESERVE (US) | 2023-06-22 | — | — | US | disclosed |
| US-11576900-B2 | Compositions and methods of reducing serum cholesterol and PCSK9 | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-02-14 | — | — | US | disclosed |
| US-8816095-B2 | Na channels, disease, and related assays and compositions | GEORGETOWN UNIVERSITY (US) | 2014-08-26 | — | — | US | disclosed |
| US-8350076-B2 | Sodium channel blockers | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-01-08 | — | — | US | disclosed |
| US-8350076-B2 | Sodium channel blockers | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-01-08 | — | — | US | disclosed |
| US-20110230442-A1 | NA CHANNELS, DISEASE, AND RELATED ASSAYS AND COMPOSITIONS | GEORGETOWN UNIVERSITY (US) | 2011-09-22 | — | — | US | disclosed |
| US-5070100-A | COMPLICATIONS OF DIABETES | ALCON LABORATORIES, INC. (US) | 1991-12-03 | — | — | US | disclosed |
| EP-0092385-B1 | HYDANTOIN DERIVATIVES FOR USE IN INHIBITING ALDOSE REDUCTASE ACTIVITY, COMPOSITIONS THEREFOR AND PROCESS FOR PREPARING SPIRO-FLUOREN COMPOUNDS | ALCON LABORATORIES, INC. (US) | 1991-06-12 | — | — | EP | disclosed |
| US-4540700-A | Treatment of diabetic complications with certain spiro-imidazolidine-diones | ALCON LABORATORIES, INC. (US) | 1985-09-10 | — | — | US | disclosed |
| US-4438272-A | COMPLICATIONS OF DIABETES | ALCON LABORATORIES, INC. (US) | 1984-03-20 | — | — | US | disclosed |
| US-4436745-A | TETRACYCLIC SPIROHYDANTOINS | ALCON LABORATORIES, INC. (US) | 1984-03-13 | — | — | US | disclosed |
| WO-1983003543-A1 | METHOD OF INHIBITING ALDOSE REDUCTASE ACTIVITY, COMPOSITIONS THEREFOR AND PROCESS FOR PREPARING SPIRO-FLUOROFLUOREN AND SPIRO-DIFLUOROFLUOREN COMPOUNDS | ALCON LAB INC (US) | 1983-10-27 | — | — | WO | disclosed |
| EP-0092385-A2 | Hydantoin derivatives for use in inhibiting aldose reductase activity, compositions therefor and process for preparing spiro-fluoren compounds | ALCON LABORATORIES, INC. (US) | 1983-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11576900-B2 | Compositions and methods of reducing serum cholesterol and PCSK9 | PCSK9, HMGCR, PCSK7 | ITGA4 4832/4885AKR1B1 9/4885AKR1A1 8/4885 |
| US-20230190710-A1 | COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 | PCSK9, HMGCR, PCSK7 | ITGA4 4832/4885AKR1B1 9/4885AKR1A1 8/4885 |
| US-12091554-B2 | Substituted polyfluorene compounds | PARG, PFAS, PARN | ITGA4 2651/4885AKR1B1 3073/4885AKR1A1 2953/4885 |
| US-20110230442-A1 | NA CHANNELS, DISEASE, AND RELATED ASSAYS AND COMPOSITIONS | CACNA1C, CACNA1B, CACNA1A | ITGA4 3334/4885AKR1B1 2543/4885AKR1A1 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.